Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

Clasificación en acciones #2013
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Precio por acción
$446.50
Última sincronización: 2026-10-19
Capitalización bursátil
$10.32B
Cambio (1 día)
-0.72%
Cambio (1 año)
1.48%
País
US
Comercio Madrigal Pharmaceuticals, Inc. (MDGL)

Categoría

Healthcare
Historial de desdoblamientos de acciones de Madrigal Pharmaceuticals, Inc. (MDGL)
La acción Madrigal Pharmaceuticals, Inc. (símbolo: MDGL) tuvo un total de 1 desdoblamientos.
El desdoblamiento más reciente ocurrió el Jul 25, 2016.
Una acción MDGL comprada antes de Jul 25, 2016 equivaldría hoy a 0.028571428571429 acciones MDGL.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
2016-07-25 1:35 x0.028571428571429 x0.028571428571429
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL